Generation and characterization of a live, bivalent vaccine against human immunodeficiency virus and Ebola virus

Simple item page
dc.contributor.authorMendoza, Emelissa J.
dc.contributor.examiningcommitteeBall, T. Blake (Immunology) Yao, Xiao-Jian (Medical Microbiology)en_US
dc.contributor.supervisorKobinger, Gary (Immunology/Medical Microbiology) Heidi Wood (Medical Microbiology)en_US
dc.date.accessioned2016-09-15T16:28:43Z
dc.date.available2016-09-15T16:28:43Z
dc.date.issued2016
dc.degree.disciplineImmunologyen_US
dc.degree.levelMaster of Science (M.Sc.)en_US
dc.description.abstractHuman immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome by targeting and destroying CD4+ T cells via its Envelope protein (Env), while Ebola virus (EBOV) causes a lethal hemorrhagic fever and targets antigen presenting cells (APCs) via its glycoprotein (GP). There are no licensed vaccines for either virus, posing a problem particularly in Africa, where succumbing to EBOV or HIV is a grim reality. We hypothesized that a replication-competent HIV expressing GP as a replacement for Env will redirect the virus from CD4+ T cells toward antigen presenting cells and act as a live, bivalent vaccine to induce cellular and humoral immune responses against both pathogens, and confer protection against a lethal EBOV challenge in mice. Recombinant HIV-1 molecular clones containing different truncations of the GP gene to replace HIV gp120 were generated and used to rescue three GP-expressing vaccines, HIV-EBOV, HIV-EBOVΔ1, and HIV-EBOVΔ2. These demonstrated tropism for the monocyte cell line, THP-1, and decreased tropism for the CD4+ T cell line, SupT1. While all vaccines induced HIV p24- and GP-specific IFN-γ-secreting T cell responses, HIV-EBOVΔ1 and HIV-EBOVΔ2 induced the most robust responses at 21 days post-vaccination (dpv), respectively. While all vaccines induced total anti-p24 and anti-GP IgG responses, HIV-EBOVΔ1 induced the most robust responses at 42 dpv. HIV-EBOVΔ1 demonstrated the highest protective efficacy against lethal EBOV challenge, followed by HIV-EBOVΔ2 and HIV-EBOV, providing 83%, 67%, and 50% survival in mice, respectively. HIV-EBOVΔ1 shows promise as a protective vaccine against EBOV, but may require further optimization and characterization regarding its mechanism of action and ability to protect against HIV.en_US
dc.description.noteOctober 2016en_US
dc.identifier.urihttp://hdl.handle.net/1993/31777
dc.language.isoengen_US
dc.rightsopen accessen_US
dc.subjectVaccineen_US
dc.subjectHIVen_US
dc.subjectEbola virusen_US
dc.subjectImmunologyen_US
dc.titleGeneration and characterization of a live, bivalent vaccine against human immunodeficiency virus and Ebola virusen_US
dc.typemaster thesisen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mendoza, E - Generation and characterization of a live, bivalent vaccine against HIV and EBOV v4.pdf
Size:
4.75 MB
Format:
Adobe Portable Document Format
Description:
Master's thesis
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.2 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
FGS - Electronic Theses and Practica